Serological tests, including enzyme-linked immunoassays and RIBA TM strip immunoblot assays, are primarily used to screen blood donations and to diagnose and confirm HCV infection. Tests for HCV RNA, including polymerase chain reaction (PCR)-based assays and the branched-DNA (bDNA) assay, are used for therapeutic monitoring and prognostics. Here, we present the development and future potential of these diagnostic tests. We also provide examples of how these tests are used to follow the progression of disease, select and adjust treatment protocols, and evaluate the efficacy of therapeutic regimens.
background Hepatitis C virus (HCV) 1 , the major causative agent of non-A, non-B hepatitis, poses a serious worldwide health problem. An estimated 100 million individuals worldwide are chronically infected with HCV, and new cases of HCV infection occur at rates of Ͼ175 000 per year in the US and Western Europe and Ͼ350 000 per year in Japan. The seroprevalence of HCV is reported to be as high as 3 .2% in the general population of northern Italy [1] . In the US, HCV seroprevalence among blood donors ranges from 0.5 per 1000 in donors younger than 20 years, to 6.9 per 1000 in donors of ages 30 -39 years [2] . Over 80% of those exposed to HCV become chronically infected, and 20% of these develop cirrhosis, possibly leading to hepatocellular carcinoma or liver decompensation. Therapy with ␣-interferon (␣IFN) has been approved by the US Food and Drug Administration (FDA); however, fewer than half of HCV-infected individuals respond to treatment, and relapse is common. No vaccine to prevent HCV infection is currently available. Because HCV infection can have such serious consequences, because its nonparenteral routes of transmission are poorly understood, and because treatment is rarely efficacious, tests that can identify and monitor HCV-infected patients are crucial for addressing this potentially life-threatening viral disease.
The breakthrough for developing diagnostic tests for non-A, non-B hepatitis came with the cloning of the HCV genome by Houghton and colleagues [3] . This work led to an antigen, with which the first diagnostic tests were developed, and to elucidation of the viral nucleic acid sequence from which numerous antigens, nucleic acid probes, and phylogenetic relationships have been derived. It is now known that HCV is an enveloped virus most closely related to the pestiviruses and flaviviruses, and contains a single-stranded, positive-sense RNA genome of 9.4 kb ( Fig. 1 ). Its one large open-reading frame encodes a polyprotein 3011 amino acids long, with structural genes at the 5Ј end and nonstructural genes at the 3Ј end of the genome. As with many RNA viruses, HCV is highly diverged-at least six major genotypes and multiple subtypes have been described (reviewed in ref. 4) . The distribution of HCV genotypes varies worldwide. Geno-types 1-3 are the most prevalent in the US; however, all six major genotypes have been noted here. Although the 5Ј-untranslated region is the most highly conserved among HCV genotypes, significant sequence variation recently has been identified even in this region of the HCV genome [5] . The genetic heterogeneity of HCV has important implications for the clinical utility of diagnostic tests.
Today, several tests are used in the diagnosis and monitoring of patients infected with HCV. Serological tests such as enzyme-linked immunoassays (EIAs) are used primarily to screen blood donations and to diagnose HCV infection in symptomatic patients. RIBA strip immunoblot assays (Chiron Diagnostics, Emeryville, CA), which are more specific and sensitive than EIAs, are particularly useful for confirmation of HCV infection. Tests for HCV RNA, including PCR-based assays and the branched-DNA (bDNA) assay (Quantiplex HCV RNA; Chiron Diagnostics), are used for therapeutic monitoring and prognostics. The development of these tests and their use in clinical practice are described in the following sections.
serological tests
The first set of clones obtained from the HCV genome was put to use in developing a serological assay for HCV infection. A first-generation EIA, in which a c100 -3human superoxide dismutase recombinant protein was the source of antigen, became commercially available in 1990. This assay was a remarkably effective means to reduce the risk of HCV transmission through blood donations, preventing an estimated 40 000 new HCV infections per year. The development of second-generation EIAs that utilize multiple antigens and exhibit greater sensitivity has led to the prevention of an additional 10 000 -15 000 cases of HCV per year [6] . Although the newest generation of EIAs for HCV infection have greatly increased sensitivities and specificities, these assays still have a relatively high false-positive rate among low-risk populations. Consequently, confirmatory serological tests often are used.
One confirmatory serological test is the RIBA HCV 2.0 strip immunoblot assay (RIBA-2 SIA), used to identify immunoreactivity against specific HCV antigens. With the four-antigen RIBA-2 SIA, detection of immunoreactivity against two or more HCV antigens is considered positive; failure to detect immunoreactivity is considered negative. Immunoreactivity against only one HCV antigen is classified as an indeterminate result, necessitating additional confirmatory tests. Recently, a third-generation RIBA HCV 3.0 SIA was developed (RIBA-3 SIA), and is now in use in Europe (Fig. 2 ). RIBA-3 SIA uses synthetic peptides from the c100 and C22 regions and recombinant proteins from the C33 and NS5 regions of the HCV genome as sources of antigen. This third-generation test has led to a substantial reduction in the number of patients' specimens classified as indeterminate. In a recent study by Damen et al. [7] , 6.7% of HCV RNA-positive patients' specimens were classified as indeterminate by RIBA-2 SIA, whereas only 0.5% were classified as indeterminate by RIBA-3 SIA. Currently under development at Chiron Diagnostics is a serotyping assay with the RIBA SIA format, which is designed to detect type-specific epitopes of HCV [8] . This assay utilizes five synthetic peptides from the NS4 region and three synthetic peptides from the core region of the HCV genome, and can distinguish between HCV genotypes 1, 2, and 3.
Despite the tremendous advances made in the technology for RIBA SIA, a substantial number of patients' specimens are classified as indeterminate. As proposed in an algorithm for diagnosis of HCV infection that incorporates sequential EIA and RIBA SIA testing [9] , further clinical evaluation and detection of HCV RNA are recommended for resolving indeterminate RIBA SIA results.
assays for hcv viremia
Assays to detect and quantify HCV RNA increasingly are being used to follow disease progression and to monitor therapeutic response in HCV-infected individuals. Unlike serological tests, which yield insight into the patient's immune response to HCV infection, HCV RNA assays provide a direct measure of viral load. As eloquently stated by Nowak and Bangham [10] , "The abundance of virus-that is, the virus load-is an important determinant of the outcome of infection with many viruses: for instance. . . [in] HIV-1 and other lentivirus infections, virus load is correlated with pathogenicity, disease stage and progression of disease; in HTLV-1. . . ; in HBV. . . ; in CMV infection. . . ; and in Lassa fever, mortality is correlated with the level of viremia." Hence, viral load measurement for chronic hepatitis C, like other viral diseases, provides unique insight into the dynamics and outcome of HCV infection.
Two widely divergent strategies are used to detect and quantify HCV RNA in clinical specimens (Fig. 3 ). The first strategy, based on PCR techniques, is performed by isolating the RNA from a specimen, reverse-transcribing it to generate cDNAs, amplifying specific nucleic acid sequences by PCR, and then using a variety of methods to detect the amplified sequences. Although PCR-based assays are used to detect low quantities of virus (1000 equivalents per milliliter, or 1 MEq/L, 1 MEq being defined as the amount of HCV RNA that generates light emission equivalent to that generated by 10 6 copies of HCV RNA reference standard), problems inherent to PCR itself lead to false-positive and false-negative results [11] and to differences in PCR results reported by different laboratories [12] . The second strategy for detecting and quantifying HCV RNA is based on bDNA technology ( Fig. 3 ). Fundamentally different from target amplification methods such as PCR, the bDNA assay directly measures nucleic acid molecules through linear signal amplification. Using synthetic oligonucleotide probes and bDNA molecules, the bDNA assay works by anchoring the HCV RNA molecules to the surface of a microtiter well and then boosting the signal through a series of hybridization steps. After introduction of a chemiluminescent dioxetane substrate, which is activated by alkaline phosphatase, the signal is quantified by photon counting in a luminometer. Because as many as 18 bDNA molecules are bound to each HCV RNA, as many as 810 separate alkaline phosphatase molecules per HCV RNA can be hybridized, thus providing tremendous enhancement of the signal.
Recently, new oligonucleotide probes were designed to extend the sensitivity of the bDNA assay and to ensure that each of the major HCV genotypes was quantified equally [13] . This improved bDNA assay, the Quantiplex HCV RNA 2.0, exhibits a specificity of 97% and sensitivity of 96% (95% confidence intervals, 91-98%). This assay is highly reproducible (CVs 21-24%) and has a linear dynamic quantification range exceeding 4 logs-from 0.2 to 120 MEq/mL. Moreover, the ability of the Quantiplex HCV RNA 2.0 to quantify equally the different HCV genotypes in clinical specimens has been documented [13] . The sensitivity of the bDNA assay for HCV RNA quantification will be extended by the ongoing improvements in bDNA technology, which include the addition of preamplifier molecules [14] and the incorporation of novel nucleotides, isocytosine and isoguanosine, into oligonucleotide probes (Collins et al., submitted). When incorporated into bDNA assays for HIV RNA quantification, these advances have extended the detection limit of the bDNA assay to as low as 50 molecules/mL.
hcv rna assays as monitors of therapeutic response
With a reliable assay for HCV RNA quantification in hand, we can now monitor changes in viral load in patients undergoing ␣IFN therapy. The goal of ␣IFN treatment for HCV infection is to eliminate or reduce the viral load of HCV, resulting in an improvement in hepatic function, a cessation or slowing of progression to liver disease, and a decrease in the infectivity of the patient. By evaluating a patient's HCV RNA concentrations before therapy, as well as during and posttherapy, a clinician may be able to determine if the patient is responding to therapy and, if so, whether that response is likely to be sustained.
Examples of viral load changes in patients treated with ␣IFN are shown in Fig. 4 [15] . Fig. 4A depicts the parallel changes in HCV RNA concentrations and serum alanine aminotransferase (ALT) concentrations in a patient who responded to ␣IFN therapy. In this patient, both HCV RNA and serum ALT decreased on initiation of therapy and remained low for at least 6 months after cessation of therapy. The profile of a nonresponding patient (Fig. 4B) shows that both HCV RNA and serum ALT decreased on initiation of therapy but then increased somewhat erratically during and after cessation of therapy. Notice in this patient that the HCV RNA values never fell below the quantification limit of the bDNA assay, and that increases in HCV RNA concentrations consistently preceded increases in serum ALT.
These two examples of responding and nonresponding patients are fairly straightforward-both patients showed changes in serum ALT and HCV RNA that were roughly parallel. However, this is not the case for other HCVinfected patients treated with ␣IFN. Changes in serum ALT and HCV RNA concentrations for three patients undergoing ␣IFN therapy are illustrated in Fig. 5 . These patients were all classified as sustained responders on the basis of normalization of their ALT values. However, examination of the HCV RNA load of these patients made it apparent that none of these patients had a virological response, even during therapy.
These examples illustrate the clinical importance of HCV RNA measurement. Even though serum ALT is a routine and relatively inexpensive test, it is a nonspecific measure of HCV disease. By contrast, HCV RNA quantification provides a direct measure of the virus and can provide valuable insight into viral dynamics during therapeutic monitoring.
hcv rna assays as predictors of therapeutic response Currently, ␣IFN is the only FDA-approved treatment for HCV infection. Unfortunately, ␣IFN treatment is expensive and plagued by unpleasant side effects. Moreover, sustained response to ␣IFN treatment occurs in Ͻ20% of HCV-infected patients. It therefore would be useful to clinicians and patients to be able to predict the likelihood of a patient's response to ␣IFN treatment. Several studies have shown that HCV RNA concentrations are predictive of response to ␣IFN therapy (see, e.g., refs. 16 -18) . The continuum of response to interferon according to HCV RNA concentrations, shown in Fig. 6 , was constructed from results of several different studies [19] . In Fig. 6 , each point includes all of the points below it. For example, there is a 38% chance of sustained response for all of the patients who have an HCV RNA load Յ1 MEq/mL. Once these studies have been confirmed, this kind of informa-tion could be used to set expectations for patients undergoing ␣IFN therapy.
Knowledge of the HCV RNA viral load also may be useful in timing ␣IFN therapy. In chronically infected patients, HCV RNA concentrations are typically quite stable. However, HCV RNA quantities do fluctuate in some patients, and may be particularly unstable in patients after ␣IFN therapy [20] . In retreatment studies, as in studies of ␣IFN treatment in therapy-naive patients, those patients with the lowest pretreatment HCV RNA concentrations appeared to be the most likely to respond to ␣IFN Reprinted with permission from Davis and Lau [15] . Fig. 6 . Continuum of response to ␣IFN therapy according to concentration of HCV RNA. therapy [21, 22] . Thus, it may be possible to monitor HCV RNA load in those patients with a poor response to an initial course of ␣IFN therapy, then recommence ␣IFN therapy at a time when HCV RNA concentrations are low, when the patient has the best chance of responding to the treatment.
In conclusion, serological assays for HCV infection play a critical role in preventing transmission of HCV through the blood supply, in diagnosing HCV infection, and in confirming an individual's infection status. With a quantitative assay for HCV RNA, clinicians may follow viral load throughout the course of disease, select and adjust treatment protocols, and evaluate the efficacy of therapeutic regimes. In combination with serotyping assays, measurement of HCV RNA concentrations may be used to predict therapeutic outcomes, so that the patient and physician can make more informed decisions about treatment. Finally, these serological and virological assays provide the basis for studies on the epidemiology, natural history, progression, and treatment of HCV infection.
